We assessed the presence and characteristics of the intracellular pathogen Chlamydophila (Chlamydia) pneumoniae in brain-tissue samples from 25 patients with late-onset Alzheimer's disease (AD) and 27 non-AD control individuals. 20/ 27 AD patients, but only 3/27 controls, were PCR-positive in multiple assays targetting the Cpn1046 and Cpn0695 genes. Culture of the organism from braintissue homogenate from one AD patient, and assessment of various chlamydial transcripts in RNA preparations from several patients, demonstrated that the organisms were viable and metabolically active in those samples. Immunohistochemical analyses showed that astrocytes, microglia, and neurons all served as host cells for C. pneumoniae in the AD brain, and that infected cells were found in close proximity to both neuritic senile plaques and neurofibrillary tangles in the AD brain. These observations confirm and significantly extend our earlier study suggesting that this unusual pathogen may play a role in the neuropathogenesis characteristic of AD.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions of individuals in the United States and many more world-wide (e.g. Clark & Karlawish, 2003) . The disease is associated with atrophy/death of neurons in particular regions of the brain and occurs in two general forms: an early-onset form that is primarily genetically determined, and a far more common late-onset, sporadic form that is not. The disease usually manifests initially as a gradual loss of short-term memory and later progresses to major cognitive dysfunction. The latter can take the form of various behavioural disorders, loss of orientation, difficulties with language, and/or other attributes (e.g. Keefover, 1996) . The rate of progression from initial manifestations to severe cognitive dysfunction varies but can be decades; death in late-onset AD patients occurs from secondary causes, not from the disease itself. Epidemiologically, the incidence of sporadic AD increases with increasing age, and it is now considered to be the most prevalent single cause of senile dementia (Breteler et al., 1992; Keefover, 1996) . Essentially, the only risk factor generally accepted as valid for influencing the development of late-onset disease is possession of the e4 allele type at the APOE locus on chromosome 19, although how this gene product engenders the neuropathology characteristic of AD remains to be fully elucidated (e.g. Huang et al., 2001; Strittmatter, 2001; Hartman et al., 2002; Bennett et al., 2003) . Not all patients expressing the e4 allele develop AD, but its presence increases risk for the disease; possession of the allele also is associated with earlier disease onset and rapid progression to cognitive dysfunction.
The means by which the neuropathology characteristic of late-onset AD is elicited is poorly understood. Neuritic senile plaques (NSP), one aspect of that pathology, are composed of b-amyloid peptide (Ab) deposits, which seem to be critical in neuronal degeneration (e.g. Citron, 2004; Takahashi et al., 2004) . Indeed, the dominant hypothesis now guiding Alzheimer's research focuses on the role of NSP in disease genesis (e.g. Hardy & Higgins, 1992; Sommer, 2002) , although a number of authors recently have questioned the general utility of the 'amyloid cascade hypothesis' as a paradigm for Alzheimer's pathogenesis (Bishop & Robinson, 2002; Lee et al., 2004) . Neurofibrillary tangles (NFT) also appear to be important in the neuropathogenesis of AD, and these are composed of modified tau protein (Goedert, 1993; Iqbal et al., 2003) . As one approach to determining the etiology of late-onset AD, several groups have investigated associations between various infectious agents and the disease, but none of these has been accepted as either etiological for disease development or involved in the exacerbation of neuropathology initiated by some other means. The viral pathogens targetted and so far discarded in these studies include measles virus, lentiviruses, adenovirus, and several other others (e.g. Pogo et al., 1987; Friedland et al., 1990) . Recent research from a group in the UK identified herpes simplex virus type 1 (HSV-1) infection as a risk factor for development of AD in people expressing APOE e4, and this remains an interesting possibility (Itzhaki et al., 1997 (Itzhaki et al., , 2001 . Several bacterial pathogens also have been investigated and dismissed in relation to involvement in AD neuropathogenesis (e.g. Renvoize et al., 1987) . In addition to NSP and NFT, inflammation of the brain is a common attribute in late-onset AD (Aisen, 1996; Hoozemans et al., 2002) , and one recent report argued that environmental factors may potentiate the brain inflammation that is characteristic of sporadic AD (Grant et al., 2002) .
In an earlier report we described an association between infection with the intracellular respiratory pathogen Chlamydophila (Chlamydia) pneumoniae and the genesis of lateonset disease (Balin et al., 1998) . We screened brain-tissue samples from 19 patients with confirmed late-onset AD and from an equal number of age-and sex-matched non-AD control individuals. The data from those studies indicated that the organism was present in about 90% of the AD brain-tissue samples assessed by highly specific and sensitive PCR assays, while only about 5% of control samples were positive in parallel assays. Further study of selected AD and control brain-tissue samples using immunohistochemical analyses, electron and immunoelectron microscopy, and chlamydial culture confirmed the presence of the organism in AD but not in control samples; astrocytes, microglia, and pericytes were identified as host cells in the AD brain, and the organism was shown to be viable and metabolically active in AD brain samples (see Balin & Appelt, 2000; Hudson, 2001 for reviews) . Subsequent studies from our group showed that some relationship exists between possession of the APOE e4 allele and the pathobiology of C. pneumoniae . We also showed that infection of human microvascular endothelial cells in culture with C. pneumoniae elicits increased expression of proteins relevant to access for the organism to the central nervous system (CNS), including N-cadherin and b-catenin (MacIntyre et al., 2002) ; interestingly, expression of occludin, a protein associated with tight junctions, was attenuated in the C. pneumoniae-infected cells. We provided additional data indicating that infection of human microvascular endothelial cells from the brain promotes passage of monocytic cells through that cell layer. The expression of various adhesion molecules was up-regulated in these experiments, including VCAM-1, ICAM-1, and others (MacIntyre et al., 2003) ; MAC-1 and other molecules expressed by monocytic cells also were increased. Importantly, work from this group has demonstrated that infection of mice with C. pneumoniae promotes the production of amyloidlike plaques in the brain of the animal (Little et al., 2004) , that the load of C. pneumoniae in the AD brain varies with APOE genotype (Gérard et al., 2005) , and that the organism cultured from the AD brain displays unusual molecular genetic and other characteristics (U.D.-W., A.P.H., submitted).
Several groups have attempted to confirm the screening data in our initial report, some of which were partially successful and others not (see Discussion). In this report we describe new experimental results supporting our earlier observations, and we provide important new information regarding the behaviour of C. pneumoniae in the AD brain relevant to its potential involvement in the AD-related neuropathogenesis process. 27 (66.7%) of those individuals were male. Tables 1 and 2 briefly summarize relevant clinical and other information for control and AD individuals, respectively.
Preparation and analysis of nucleic acids
Total nucleic acids were prepared from each sample from every AD and non-AD control patient via homogenization in 65 1C buffered phenol, as described in Balin et al. (1998) and Gérard et al. (2000 Gérard et al. ( , 2001 Gérard et al. ( , 2002 . Extreme care was taken to avoid cross-contamination of samples in the preparative procedure. Pure DNA was prepared from total nucleic acid mixtures by extensive treatment with RNase A plus RNase T1 (Invitrogen, Carlsbad, CA), followed by several extractions in phenol:chloroform, and then precipitation in ethanol. The brain-tissue samples from each AD patient and non-AD control individual were screened in a blinded fashion for the presence of C. pneumoniae chromosomal DNA by PCR, using two independently targetted assay systems. One nested assay system used primers targetting the gene encoding a probable aromatic amino acid hydroxylase (Cpn1046), which is present in the genome of C. pneumoniae but not in those of other chlamydial species. The second assay targetted the gene encoding the major outer membrane protein of the organism (Cpn0695); primers for the latter gene are specific for the Cpn0695 coding sequence of C. pneumoniae, do not amplify DNA sequences of the MOMP-encoding gene of C. trachomatis or other Chlamydia, and are given in Balin et al. (1998) , as are detailed cycling conditions. Primers targetting the Cpn1046 gene were: (outer) 5
0 . Cycling conditions were the same as those for the Cpn0695 gene except that annealing for both outer and inner rounds was done at 52 1C. Samples were screened by PCR in duplicate independently by two investigators and were scored as positive for C. pneumoniae DNA only if the duplicate PCR assays were both positive for each targetted gene in each investigator's hands; in cases of discrepancy, a third independently targetted assay was used. Real-time PCR analyses to determine relative C. pneumoniae load in 50-mg samples of AD and non-AD control brain tissue were performed as described in Gérard et al. (2005) , using primers and cycling conditions described in that report. Data for bacterial load in AD and control samples so assessed were determined in triplicate, and then averaged. Bacterial load in the AD brain samples are presented as relative bacterial load indexed to the average bacterial load among the non-AD control samples. Determination of the genotype at APOE for each patient sample was carried out as described (Hixson & Vernier, 1990; Balin et al. 1998) . Pure RNA for reverse transcriptase (RT)-PCR analyses was prepared from total nucleic acid mixtures from brain-tissue samples by extensive treatment with DNase I (RQ1, Promega Biotech, Madison, WI), followed by extraction in phenol:-chloroform, and then precipitation in ethanol (Gérard et al., 2000 (Gérard et al., , 2001 (Gérard et al., , 2002 . The lack of DNA remaining in the samples was confirmed by standard PCR targetting the actin gene in RNA preparations prior to reverse transcription (RT). RT reactions were carried out as described in earlier papers, using the MuLV enzyme (Invitrogen, Carlsbad, CA) and random hexamers as primers (Gérard et al., 2000; Byrne et al., 2001) . Amplifications of the targetted mRNA/cDNA so produced encoding either primary transcripts from the rRNA operon or the Cpn1046 gene product were performed as described in Gérard et al, (2000) and Byrne et al. (2001) , using primers given in those publications.
Culture of C. pneumoniae from brain tissues
Chlamydial culture was carried out using HEp-2 cells grown in Iscove's Modified Dulbecco's media with 10% fetal bovine serum (FBS), 2mM L-Glu and 10 mg mL À1 gentamycin. The medium contained 1 mg mL À1 cycloheximide during the infection process. AD brain tissue from the hippocampus of patient AD11/Tor was homogenized in a dounce containing sucrose-phosphate-glutamic acid (SPG) buffer. The diluted homogenate was added to HEp-2 monolayers in 6-well plates and centrifuged for 1 h at 750 g at 30 1C. Cells were subsequently incubated for 3 days at 35 1C in the presence of 5% CO 2 . The supernatants and/or harvested and lysed cells then were passaged on fresh HEp-2 monolayers, as given above, and incubated again for at least 3 days. To monitor development of inclusions during the culture, samples were stained with a genus-specific fluorescein isothiocyanate (FITC)-labelled antibody targetting chlamydial lipopolysaccharide (LPS) (Pathfinder TM , BioRad Corp., Hercules, CA), or a monoclonal antibody specifically targetting the C. pneumoniae major outer membrane protein (Dako, Carpinteria, CA), with appropriate secondary antibody (see below).
In situ hybridization
The in situ hybridization system targetted a DNA sequence within the Cpn1046 gene (Gérard et al., 2005) . This gene encodes a putative aromatic amino acid hydroxylase and is not present in other chlamydial species (Read et al., 2000) . The sequence of the in situ hybridization probe (5 0 -AGCCAAT-CACTCCAACGTGCATACTCGACC-3 0 ) is unique in GenBank. Six micrometer sections were cut from frozen brain tissues, fixed in buffered 4% paraformaldehyde, hybridized with the digoxigenin-labelled probe at 35 1C, washed extensively, and developed with an alkaline phosphatase-labelled sheep antidigoxigenin secondary antibody. A Nikon Eclipse E600 microscope was used for viewing and photography.
Immunohistochemical analyses
Acetone-fixed frozen AD brain tissues were cut into 6-8 mm sections using standard methods for immunofluorescence and the avidin-biotin-complex (ABC) method (e.g. Drescher & Whittum-Hudson 1996a, b) . Chlamydia pneumoniae-infected cells were identified in some cases by labelling with a monoclonal antibody targetting the chlamydial LPS (Pathfinder   TM   ) . In other experiments, the organism was identified using a monoclonal antibody targetting the C. pneumoniae major outer membrane protein (Dako), in combination with a secondary antibody. In some double immunolabelling studies, Pathfinder TM -stained AD braintissue sections were also stained with a monoclonal antibody targetting the modified tau protein that comprises NFT (PHF-1; Sternberger Monoclonals, Lutherville, MD) or a monoclonal antibody targetting the Ab that comprises NSP (Signet Laboratories, Dedham, MA). In other double immunolabelling experiments, Pathfinder TM -labelled AD brain-tissue sections were subsequently stained with a polyclonal rabbit antibody targetting glial fibrillary acid protein (GFAP; Sternberger) to identify astrocytes, a goat antibody targetting inducible nitric oxide synthase to identify microglia (iNOS; Transduction Laboratories, Lexington, KY), or a monoclonal antibody targetting neuron-specific microtubule-associated protein (MAP-2; Sigma, St Louis, MO). Biotinylated secondary antibodies were horse antimouse (1 : 100 dilution) or goat antirabbit antibody (1 : 100, Vector Laboratories, Burlingame, CA). In all double-staining experiments, primary antibodies were added to sections simultaneously for 1-4 h. Following rinsing and reblocking, sections were incubated with secondary antibody overnight at 4 1C, rinsed, and the ABC Elite reagent (Vector) was applied for 45-60 min. Reaction was developed with freshly prepared aminoethylcarbazole and hydrogen peroxide; after washes, sections were counterstained with Harris' hematoxylin. Sections were examined using a Nikon E600 microscope with epifluorescence. In all immunohistochemical analyses, appropriate controls were carried out in parallel in each staining experiment, including staining with normal mouse and/or rabbit serum, and staining with an irrelevant or no primary antibody.
Results
PCR screening of brain-tissue samples from AD and non-AD control individuals Two sensitive, highly specific, and independently targetted PCR assays were used to screen for C. pneumoniae DNA sequences in nucleic acid preparations from multiple brain samples from each of 25 patients with late-onset AD, and in parallel preparations from brain samples from each of 27 non-AD control individuals (Tables 1 and 2 ). Among the AD samples, those from 20 patients (80.0%) were consistently PCR-positive in both assay systems over four repeats each (Table 1 , Fig. 1a) ; these results are consistent with our earlier published data (Balin et al., 1998) . Two AD patients from whom samples were procured had been diagnosed with both AD and Parkinson's disease (PD, patients AD16, AD17); interestingly, samples from both were PCR-positive in the screening assays. In contrast to the AD patient results, only three samples (11.1%) from the 27 control individuals were consistently, although weakly, PCR-positive for C. pneumoniae DNA in repeated assays (Table 2 , Fig. 1a) ; two control samples were procured from patients diagnosed with only PD (patients C9, C10), and a sample from one of these was extremely weakly PCR-positive. Determination of genotype at APOE for AD patients and non-AD controls indicated that samples from four of the 27 control individuals possessed the e4 allele type, and each of these was an e3/e4 heterozygote. Consistent with our own and many other studies, the e4 allele was present in a high proportion of the AD samples (14/25, 56.0%); two patients were e4 (1) 100-bp size standards; (2) Cpn0695 positive control (C. pneumoniae DNA as template); (3) Cpn0695 negative control (water as template); (4) Cpn1046 positive control (C. pneumoniae DNA as template); (5) Cpn1046 negative control (water as template); (6) and (7) Cpn0695-and Cpn1046-targetted assays, respectively, using nucleic acids from patient AD7/AA; (8) and (9) Cpn0695-and Cpn1046-targetted assays, respectively, using nucleic acids from control C2/AA; (10) and (11) Cpn0695-and Cpn1046-targetted assays, respectively, using nucleic acids from patient AD14/Tor. The Cpn0695 amplification product = 347 bp; that from Cpn1046 = 521 bp. (b) Representative results from real-time PCR analyses of AD and non-AD control samples for relative C. pneumoniae load. Total nucleic acids, then pure RNA and cDNA, were prepared from 50-mg brain-tissue samples as given in Materials and methods; assays and analysis were performed as given in that section. Standard error is shown. (c) Representative RT-PCR results from assays targetting primary rRNA gene and Cpn1046 transcripts in cDNA preparations from AD and non-AD control brain samples. Lanes are: (1) 100-bp size standards; (2) primary rRNA gene transcript positive control (C. pneumoniae DNA as template); (3) primary rRNA gene transcript negative control (water as template); (4) and (5) product from RT-PCR targetting primary rRNA gene transcripts in samples AD6/AA and AD14/Tor (both HP); (6) no product from RT-PCR targetting primary rRNA gene transcripts in sample AD24/ SP (TCx); (7) Cpn1046 mRNA/cDNA positive control (C. pneumoniae DNA as template); (8) Cpn1046 mRNA/cDNA negative control (water as template); (9) and (11) product from RT-PCR targetting Cpn1046 mRNA/ cDNA in samples AD6/AA and AD14/Tor (both HP); (10) product from RT-PCR targetting Cpn1046 mRNA/cDNA in sample C12/SP (TCx). Amplification product sizes are given in (a).
homozygotes, and the rest were e3/e4 heterozygotes, except for patients AD15/LA and AD16/LA, who were e2/e3. Thus, PCR-based screening of AD but not of control brain samples showed a high rate of positivity for DNA sequences from C. pneumoniae.
We used real-time PCR to assess the variation in bacterial burden among PCR-positive AD patient samples, and among AD patient samples relative to that in non-AD control samples. The data shown in Fig. 1b demonstrate that the relative bacterial load varied among AD brain-tissue samples, as expected, but that it is always far heavier than that found in PCR-positive non-AD control brain samples (see also Gérard et al., 2005) .
The simple presence of DNA from C. pneumoniae or any other organism in a clinical sample does not indicate a priori that the organism was viable and/or metabolically active at the time the sample was procured. In earlier studies, we assessed these characteristics for Chlamydia in infected clinical samples by determining whether primary transcripts from the rRNA operons were present in the samples at issue (e.g. Gérard et al., 1998 Gérard et al., , 2000 Gérard et al., , 2002 . The representative data in Fig. 1c demonstrate that primary rRNA gene transcripts indeed were plentiful in each of the four patient samples subjected to this analysis. We also assessed the presence of mRNA from the C. pneumoniae Cpn1046 gene, and transcripts from this gene were present in each RNA/cDNA preparation so examined as well. Thus, for the samples tested, C. pneumoniae in the AD brain appears to be metabolically active, as judged from the presence of primary rRNA gene transcripts in those samples (see Gérard et al., 1998) .
Culture of C. pneumoniae from AD brain tissues
A more classical means to confirm both the presence and viability of any organism in a clinical sample is to culture the organism from that sample. We attempted to culture C. pneumoniae from selected brain-tissue samples shown to be PCR-positive for the organism. One sample chosen for culture analysis was hippocampal tissue from patient AD11/ T or (Table 2) , because real-time data indicated an exceptionally high load of organism in that sample. Tissue homogenates from that sample were cultured using HEp-2 cells as in vitro host, and the presence and identity of the organism were assessed using a monoclonal antibody that specifically targets the C. pneumoniae major outer membrane protein. The image in Fig. 2a demonstrates that sample AD11/T was culture-positive for the organism, and the PCR data in Fig. 2b targetting the Cpn1046 gene, which is C. pneumoniae-specific, confirm that the organism cultured was indeed C. pneumoniae. Thus, culture of C. pneumoniae from this AD brain sample was successful, confirming the viability of the organism in that sample. In another context we will present detailed molecular genetic and cell biological analyses of this and other isolates from AD brain tissues (U.D.-W., A.P.H., submitted).
In situ hybridization analyses
To demonstrate the presence of C. pneumoniae in the AD brain by a fully independent method, we developed an in situ hybridization system targetting the Cpn1046 gene. This system was used to screen tissue sections from the hippocampus and temporal cortex from seven patients with late-onset AD, and from two control individuals. The images in Fig. 3 present representative data from these experiments. Figure 3a shows that when the digoxigeninlabelled probe was hybridized to tissue sections from the temporal cortex of a non-AD control individual (patient C5/ AA; Table 1 ) no signal was identifiable. In contrast, a clear signal was observed when sections from the hippocampus (Fig. 3b ) and temporal cortex (Fig. 3c ) of PCR-positive AD patients were hybridized. Examination of some hybridized sections at high magnification identified inclusions containing normal-appearing C. pneumoniae ( Fig. 3d and e) .
Relationship of C. pneumoniae -infected cells to NSP and NFT
An important issue regarding any potential role for C. pneumoniae in the neuropathogenesis of AD is whether cells infected with the organism are located in proximity to NSP and/or NFT in affected brain tissues. To assess this question, we used monoclonal antibodies to label separately and specifically each of those structures in individual AD brain-tissue sections, and C. pneumoniae-infected cells in those same tissue sections; in these analyses, sections from four AD brain samples were examined (patients AD2/AA, AD5/AA, AD11/Tor, AD14/Tor). The representative doubleimmunostained images in Fig. 4 confirm that infected cells in the AD brain ( Fig. 4a and c) colocalize with both NSP (Fig. 4b) and NFT (Fig. 4d) . Thus, C. pneumoniae-infected cells in brain-tissue samples from AD patients were located in close proximity to the major neuropathological structures characterizing the disease.
Immunohistochemical analyses to identify host cells in the AD brain
An issue of significant interest concerns the identity of the host cell(s) infected by C. pneumoniae in the AD brain, because some cell types infected with the organism may contribute more than others to the inflammation or other aspects of neuropathology that characterize the disease. Previous work from this laboratory used double immunostaining to identify astrocytes and microglia as hosts in the affected CNS (Balin et al., 1998) , and repeated experiments confirmed this to be the case. That is, astrocytes infected with C. pneumoniae were easily identifiable in brain-tissue sections double-labelled with a monoclonal antibody targetting GFAP and a monoclonal antibody targetting the chlamydial LPS ( Fig. 5a and b) . Similarly, infected microglial cells were identified by double immunostaining with the anti-LPS monoclonal antibody and a monoclonal antibody targetting iNOS ( Fig. 5c and d) . In our earlier study, we did not investigate whether neurons were infected with C. pneumoniae in the AD brain. The data given in Fig. 5e and f clearly demonstrate that this is the case, however; in other words, cells labelled with a monoclonal antibody targetting neuron-specific microtubule-associated protein also labelled clearly with the monoclonal antibody targetting the chlamydial LPS. The number of cells doubly labelled with these two antibodies vs. the number labelled only with the neuron-specific antibody was assessed in 10 fields at low power and indicated that c. 20% of neurons were infected in these samples. Thus, in addition to astrocytes and microglia, neurons often serve as host cells for C. pneumoniae in the AD brain.
Discussion
Chlamydia pneumoniae is an unusual respiratory pathogen that was defined as a species only relatively recently (e.g. Grayston et al., 1990 and references therein) . Like all chlamydiae, this organism is an obligate intracellular bacterial pathogen that is acquired at mucosal surfaces, in this case the oral and nasal mucosa (Campbell & Kuo, 2002) . Chlamydia pneumoniae is known to be a significant etiological agent for acute respiratory infections, including community-acquired pneumonia and bronchitis, and some recent studies have implicated the organism in more severe pulmonary pathologies, including sarcoidosis, asthma, and chronic obstructive pulmonary disorder (e.g. Hahn et al., 1991; Grayston et al., 1993; von Hertzen, 1998; Campbell & Kuo, 2002; Webley et al., 2005) . Interestingly, infection with C. pneumoniae has been implicated in several nonpulmonary clinical entities such as inflammatory arthritis , and atherosclerosis (e.g. Belland et al. 2004 for review) . Importantly for the present study, this pathogen also has been associated with CNS infections (Koskiniemi et al., 1996) , cerebrovascular disease (Wimmer et al., 1996) , and even with multiple sclerosis (Sriram et al., 1999) . We previously reported an association between infection with C. pneumoniae and late-onset AD (Balin et al., 1998) , and in the present report we confirm and extend those earlier findings. Specifically, we demonstrate here that brain-tissue samples from a high proportion of patients with AD, but not those from age-/sex-matched non-AD controls, are PCRpositive for chromosomal DNA from this organism. That the organism is viable within the AD brain was shown by culture of the organism from relevant brain samples; data from RT-PCR analyses to identify primary rRNA gene transcripts from C. pneumoniae in infected brain tissues indicated metabolic activity of the organism in those tissues. We confirmed that astrocytes and microglia are common host cell types for the organism in the AD brain, and importantly we demonstrated that c. 20% of neurons are infected as well. Finally, we confirmed that C. pneumoniaeinfected cells in the AD brain are found in close association with NFT, and we provided evidence that infected cells also are commonly found in areas of NSP. While none of these observations demonstrates a causal relationship between CNS infection with C. pneumoniae and the neuropathogenesis characteristic of AD, they are consistent with such a relationship. It is of considerable interest that, in addition to astrocytes and microglia, neurons can and frequently do function as host cells for C. pneumoniae in the AD brain. As with all chlamydial species, during normal active infection the developmental cycle of C. pneumoniae frequently terminates with lysis of the host cell (e.g. Hatch 1999 ). Late-onset AD is, of course, characterized by atrophy and death of neurons in specific brain regions, and thus active C. pneumoniae infection of neurons could contribute to the death of those cells in patients with the disease. In our AD brain-tissue samples, we routinely found about 20% of neurons to be infected with the organism. The patient samples available to us from all sources were from end-stage individuals, as expected. It would be of interest, however, to assess the relative level of neuronal infection with C. pneumoniae in brain-tissue samples from patients at earlier stages of the disease, because this information might indicate whether cell killing by the organism contributes significantly to overall neuronal loss. It is also of interest that CNS cells of all types infected with C. pneumoniae colocalize rather closely with both NSP and NFT, as such a relationship would be expected if the organism contributed in one or more ways to the production of these neuropathological structures. In our earlier study, we rarely identified infected cells in regions of the AD brain not usually characterized by neuropathology, except in samples from those patients generally showing extremely high bacterial loads in normally affected regions (Balin et al., 1998) ; this proved to be the case in the present sample set as well.
As indicated above, since publication of our original study several groups have tried to replicate various aspects of our work, with erratic success. One group could not identify C. pneumoniae in paraffin-embedded brain tissues from 12 confirmed and 13 suspected late-onset AD patients using either PCR or immunohistochemical (IHC) analyses (Nochlin et al., 1999) . In a similar study, the organism was not identified in any of 20 paraffin-embedded AD brain samples, again using either IHC or PCR (Gieffers et al., 2000) . Similar results recently were obtained by a group in England (Taylor et al., 2002) . In a fourth study, multiple samples from each of 15 confirmed AD and five non-AD control brains were assessed by PCR, and each sample was assayed independently several times (Ring & Lyons, 2000) ; samples were prepared from frozen brain tissues, and culture of the organism from some samples was attempted. Cultures were negative for all samples attempted, but a few positives were obtained in PCR screening. The recovery of high-quality template for PCR from paraffin-embedded or otherwise fixed tissue is often unreliable, and this may explain in part some negative results À only frozen braintissue samples were used in our studies and in that of Ring & Lyons (2000) . However, it is difficult to understand why the tissues used in two of the studies were negative by IHC, since one group reported success in identifying C. pneumoniae by this method in 11/12 paraffin-embedded AD brain samples (Ossewarde et al., 2000) ; controls were negative, including those from individuals with other neurological diseases. In our own work, in negative IHC studies, and in the positive study, the same mAb targetting the C. pneumoniae MOMP or LPS were employed, suggesting differences in technique in obtaining positive results. Another report provides insight into the mixed positive and negative PCR data from the studies above (Mahony et al., 2000) . This study employed replicate PCR assays and probit regression analyses to show that DNA from up to 85% of the frozen AD brain samples analysed was PCR-positive for C. pneumoniae if enough replicates were performed; multiply assayed controls were always PCR-negative. These data suggest that identification of chlamydial DNA in such source materials requires both careful template preparation and repetitive analyses. Recently, a randomized clinical trial was reported that employed a combination antibiotic approach for the treatment of AD (Loeb et al., 2004) : doxycycline and rifampin were given orally daily for 3 months to patients with probable AD and mild/moderate dementia. The primary outcome was a change in the Standardized AD Assessment Scale cognitive subscale (SADAScog) at 6 months. Secondary outcomes were changes in the SADAScog at 12 months and analysis of dysfunctional behaviour, depression, and functional status. Results showed less decline in the SADAScog score at 6 months in the antibiotic vs. the placebo group; the SADAScog score at 12 months in the antibiotic vs. the placebo groups was not significantly different. However, the antibiotic group showed less dysfunctional behavior at 3 months, and at 12 months the antibiotic group showed reduced decline in mini-mental status exam scores. Correlations with changes in C. pneumoniae infection were not apparent as defined by serotitering and PCR of blood. Data from this trial did not show that attenuation of decline in psychometric parameters resulted from the effects of antibiotics, but the analyses for change in infection may have been less than fully adequate, because the sampling of antibodies and organism in blood is not always indicative of what has occurred in tissues. Animal modelling will be required to define in detail how chlamydial infection might result in AD-related pathological change in the CNS and to provide a better understanding of infection parameters. We have developed a promising animal model for these purposes and are now using it to investigate the mechanisms possibly used by C. pneumoniae to engender AD neuropathology (Little et al., 2004) .
